

**Registered Office :**

Plot No. PF/21, Nr. Acme Pharma,  
Opp. Teva Pharma, Sanand GICD - II,  
Sanand, Ahmedabad – 382110, Gujarat (INDIA)

**CIN.: L24230GJ2015PLC085451**



**Date: October 11, 2023**

**To,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai - 400051.

**Dear Sir/Madam,**

**Subject: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2023.**

**Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE002D01012)**

We submit herewith the confirmation certificate and details of Share certificates Dematerialized for the period ended on September 30, 2023 received from Kfin Technologies Limited, Registrar and Share Transfer Agent (RTA) of the Company as per regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on September 30, 2023.

This is for your information and records.

Thanking you,  
**For, Sotac Pharmaceuticals Limited**

**PATEL**  
**SHARADKUMAR**

Digitally signed by PATEL SHARADKUMAR  
DN: cn=IN, postalCode=380051, st=GUJARAT, street=68 VANBHAV BUNGLOWS  
PART 2 AHMEDABAD CHATTOOANEAR SUN AND STEP CLUB 380061,  
l=AHMEDABAD, o=Personal, title=7162,  
serialNumber=0696672bada9852ac46529012e3e32ed18b9489a3ecf37a671aa  
dca=1f10030, pseudonym=716220230121154626539,  
2.5.4.20=b205f5d5261b0a0b484230ec84cda0ab339e2ce1731350af6a554916c  
2ee16c, email=SHARADPHARMACEUTICAL@YAHOO.COM, cn=PATEL  
SHARADKUMAR  
Date: 2023.10.11 18:45:51 +05'30'

**Sharadkumar Dashrathbhai Patel**  
**Chairman and Managing Director**  
**DIN: 07252252**

**Place: Ahmedabad**

**Encl: - A/a**



KFIN/MRVS/STOP/74(5) E/1  
Date: 05.10.2023

The Company Secretary  
M/S. Sotac Pharmaceuticals Limited  
Plot No. PF-21, Nr. ACME Pharma, Opp. Teva  
Pharma Sanand GIDC-II, Sanand  
Ahmedabad – 382110.

Dear Sir(s),

**Sub: Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories & Participants) Regulations 2018 ('Regulations') for the quarter ended September 30, 2023**

With reference to the above captioned Regulations, we hereby confirm that the during the period from July 01, 2023 to September 30, 2023, we have not received any requests for dematerialization/rematerialization of shares of Sotac Pharmaceuticals Limited, as required under Regulation 74(5) of SEBI (Depositories and participants) Regulations 2018.

Thanking you,

Yours faithfully,  
For KFIN TECHNOLOGIES LIMITED



Kishore B  
Manager